Project Number: 1245-31000-103-09
Start Date: Sep 01, 2013
End Date: Aug 31, 2016
The Sponsor will provide transcription activator-like effector nucleases (TALENs) that have been validated in vitro for the ability to target and modify the NANOS3 gene. UMD-CP and ARS scientists will use these enzymes to disrupt the NANOS3 gene by site directed mutagenesis. UMD and ARS scientists will inject TALENs into zygotes which will then be transferred into recipient females Offspring will be screened for genetic alterations in the NANOS3 gene expected to result in SSC deficient males. The animals will be housed and reared in ARS facilities. ARS, UMDCP & the Cooperator will evaluate all data and publish jointly.